Key Highlights
- Avalyn Pharma will host Citi Biotech Private Visit Day on April 24, 2025.
- A virtual one-to-one investor meeting sponsored by the company will be held to highlight its pipeline of inhaling drugs.
Key facts
- Lead product AP01 is currently undergoing a phase 2B trial of progressive pulmonary fibrosis (PPF).
- AP02 is a Hedoni inhalation in the first phase of idiopathic pulmonary fibrosis (IPF).
Key background
Avalyn Pharma Inc., a clinical-stage biopharmaceutical company in the United States, is mapping the process of inhalation treatment for more severe lung diseases such as more severe pulmonary fibrosis. In this case, progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) can lead to fibrosis in the lung tissue, thereby reducing respiratory capacity and quality of life. As conventional oral medications are limited by systemic side effects, Avalyn is expected to revolutionize treatment with topical drug delivery.
Its highest asset, AP01, is the refined inhalation form of Pirfenidone. In the ongoing Phase 2B study, in the fog (maximizing safety and tolerance of inhalation), PPF indication has been in the study. The product has been evaluated in more than 150 patients and has a tolerant safety and a reassuring indication of effectiveness. By acting on the lungs themselves, AP01 hopes to experience unnecessary effects when taking oral products to produce therapeutic effects.
Avalyn also advances AP02, an inhalation formula for the anti-fibrotic compound Nintedanib. The two-stage 1 AP02 test has been completed and has tolerant and safety at various doses. The treatment of IPF is a limited treatment alternative disease and a strong disease that has unmet medical needs.
By visiting Citi Biotech’s private access day, Avalyn’s goal is to increase investor engagement, emphasize its innovative characteristics, and build momentum for its critical pipeline. These investor meetings provide an important platform on which the company can spread data insights, articulate tomorrow’s vision, and establish itself as an innovative lung medicine pioneer. This achievement is another milestone in the Avalyn development cycle, bringing targeted, targeted therapies to the market.
